ASTHMA RESEARCH STUDY
The goal of asthma treatment is to achieve and maintain asthma control and to reduce the future risk of exacerbations. Inhaled corticosteroids (ICS) are considered as the most effective anti- inflammatory treatment for all severities of asthma.
Because of this, Teva is developing generic Fluticasone Propionate, equal to the current FDA-approved product called Flovent HFA. This study will examine whether the proposed generic medicine is equal to the product that is already available for treating asthma.
This study will last approximately 1 month and will include up to 4 office visits. All visits are conducted locally in Salt Lake City, Utah.
Benefits of Participating:
Receive compensation up to $300.00 for time and travel Study medications and Albuterol provided.
No cost to participate.
No insurance needed.
Completely voluntary, no obligation to continue. To Qualify, You Must:
Be between 18 and 75 years old.
Be diagnosed with Asthma.
Be taking an inhaler for Asthma consistently.
To find out more call us at 801-363-7353 or submit the form below. By contacting us, you are in no way obligated to participate. All information submitted is kept strictly confidential and is never shared or sold to third parties.